European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Dynastat, parecoxib, Date of authorisation: 22/03/2002, Revision: 38, Status: Authorised

Submitted by Anonymous (not verified) on 10 October 2024 - 14:50

Human medicines European public assessment report (EPAR): Dynastat, parecoxib, Date of authorisation: 22/03/2002, Revision: 38, Status: Authorised

Fourth veterinary big data stakeholder forum, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 October 2024, 10:00 (CEST) to 14 October 2024, 15:00 (CEST)

Submitted by Anonymous (not verified) on 10 October 2024 - 14:47

Fourth veterinary big data stakeholder forum, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 October 2024, 10:00 (CEST) to 14 October 2024, 15:00 (CEST)

Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 10 October 2024 - 13:30

Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 10 October 2024 - 13:20

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Spevigo, spesolimab, Date of authorisation: 09/12/2022, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 10 October 2024 - 13:03

Human medicines European public assessment report (EPAR): Spevigo, spesolimab, Date of authorisation: 09/12/2022, Revision: 1, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More